Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $69.90, with 8.66 million shares of worth about $605.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.30% during that period and on April 09, 2025 the price saw a gain of about 4.22%. Currently the company’s common shares owned by public are about 588.60M shares, out of which, 574.31M shares are available for trading.
Stock saw a price change of -2.98% in past 5 days and over the past one month there was a price change of 2.21%. Year-to-date (YTD), EW shares are showing a performance of -5.58% which decreased to -24.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $95.25 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.67 million. The stock is currently trading -0.92% below its 20-day simple moving average (SMA20), while that difference is down -2.23% for SMA50 and it goes to -2.74% lower than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 588.60M outstanding shares and institutions hold larger chunk of about 87.50% of that.
The stock has a current market capitalization of $40.94B and its 3Y-monthly beta is at 1.08. PE ratio of stock for trailing 12 months is 28.54, while it has posted earnings per share of $2.45 in the same period. Its PEG reads 3.39 and has Quick Ratio of 3.45 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 5.53% while standing at 3.03% over the month.
Stock’s fiscal year EPS is expected to rise by 0.98% while it is estimated to increase by 12.17% in next year. EPS is likely to grow at an annualized rate of 8.41% for next 5-years, compared to annual growth of -2.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on January 30, 2025 offering a Buy rating for the stock and assigned a target price range of between $75 and $90 to it. Coverage by Wolfe Research stated Edwards Lifesciences Corp (EW) stock as an Underperform in their note to investors on January 16, 2025, suggesting a price target of $60 for the stock. On December 16, 2024, BofA Securities Upgrade their recommendations, while on October 11, 2024, Morgan Stanley Resumed their ratings for the stock with a price target of $70. Stock get a Hold rating from Jefferies on September 18, 2024.
